Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile

References

• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932–6
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74
   PubMed Web of Science ®Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7
   PubMed Web of Science ®Google Scholar
• Lee ES, Oh MJ, Jung JW, et al. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 2007;22:94–8
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti- VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605–8. Epub 2003 Jan 21
   PubMed Web of Science ®Google Scholar
• Haigh JJ. Role of VEGF in organogenesis. Organogenesis 2008;4:247–56
   PubMedGoogle Scholar
• Hornig C, Barleon B, Ahmad S, et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000;80:443–54
   PubMed Web of Science ®Google Scholar
• Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443–8
   PubMed Web of Science ®Google Scholar
• Rodrigues P, Furriol J, Tormo E, et al. The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat 2012;133:769–78
   PubMed Web of Science ®Google Scholar
• Rippl PK, Angsenlehner UL, Enner WR, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468–71
   Google Scholar
• Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and preeclampsia. Mol Hum Reprod 2004;10:321–4
   PubMed Web of Science ®Google Scholar
• Shim JY, Jun JK, Jung BK, et al. Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol 2007;197:271.e1–4
   Google Scholar
• Cunha VM, Grecco RL, Paschoini MC, et al. Genetic polymorphisms of vascular endothelial growth factor in pre-eclampsia. Rev Bras Ginecol Obstet 2011;33:158–63
   PubMedGoogle Scholar
• ACOG Committee on Practice Bulletins – Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002;99:159–67
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Goldman-Wohl D, Yagel S. Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol 2002;187:233–8
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Musci TJ, et al. Pre-eclampsia: an endothelial cell disorder. Am J Obstet Gynaecol 1989;6:1200–4
   Google Scholar
• Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95:884–91
   PubMed Web of Science ®Google Scholar
• Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109:168–80
   PubMed Web of Science ®Google Scholar
• Brownbill P, McKeeman GC, Brockelsby JC, et al. Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. Endocrinology 2007;148:4734–44
   PubMedGoogle Scholar
• Powers RW, Roberts JM, Cooper KM, et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005;193:185–91
   PubMed Web of Science ®Google Scholar
• Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368–74
   PubMed Web of Science ®Google Scholar
• Varughese B, Bhatla N, Kumar R, et al. Circulating angiogenic factors in pregnancies complicated by pre-eclampsia. Natl Med J India 2010;23:77–81
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol 2004;190:1541–7
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004;89:770–5
   PubMed Web of Science ®Google Scholar
• Reimer T, Rohrmann H, Stubert J, et al. Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis. J Matern Fetal Neonatal Med 2013;26:263–9
   PubMed Web of Science ®Google Scholar
• Laivuori H. Genetic aspects of preeclampsia. Front Biosci 2007;12:2372–82
   PubMed Web of Science ®Google Scholar
• Cross JC. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin Genet 2003;64:96–103
   PubMed Web of Science ®Google Scholar
• Boutsikou T, Malamitsi-Puchner A, Economou E, et al. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006;82:235–9
   PubMed Web of Science ®Google Scholar
• Schlembach D, Wallner W, Sengenberger R, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007;29:407–13
   PubMed Web of Science ®Google Scholar
• Szentpéteri I, Rab A, Kornya L, et al. Gene expression patterns of vascular endothelial growth factor (VEGF-A) in human placenta from pregnancies with intrauterine growth restriction. J Matern Fetal Neonatal Med 2013;26:984–9
   PubMed Web of Science ®Google Scholar
• Lachmeijer AM, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002;105:94–113
   PubMed Web of Science ®Google Scholar
• Chedraui P, Solis EJ, Bocci G, et al. Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. J Matern Fetal Neonatal Med 2013;26:226–32
   PubMed Web of Science ®Google Scholar